US 12,168,802 B2
Methods of diagnosing and treating CD55 deficiency, hyperactivation of complement, angiopathic thrombosis and protein losing enteropathy (CHAPLE), a newly identified orphan disease
Michael J. Lenardo, Bethesda, MD (US); Helen Su, Bethesda, MD (US); Ahmet Oguzhan Ozen, Istanbul (TR); William Andrew Comrie, Rockville, MD (US); Kaan Boztug, Vienna (AT); and Rico Chandra Ardy, Vienna (AT)
Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed by The United States of America, as represented by the Secretary, Dept. of Health and Human Services, Bethesda, MD (US)
Filed on Jan. 13, 2023, as Appl. No. 18/154,745.
Application 18/154,745 is a division of application No. 16/333,561, abandoned, previously published as PCT/US2017/051413, filed on Sep. 13, 2017.
Claims priority of provisional application 62/394,630, filed on Sep. 14, 2016.
Prior Publication US 2023/0295730 A1, Sep. 21, 2023
Int. Cl. A61K 39/395 (2006.01); A61K 38/12 (2006.01); C12Q 1/6827 (2018.01); C12Q 1/6851 (2018.01); C12Q 1/6883 (2018.01); G01N 33/68 (2006.01); C07K 16/40 (2006.01)
CPC C12Q 1/6883 (2013.01) [A61K 38/12 (2013.01); C12Q 1/6827 (2013.01); C12Q 1/6851 (2013.01); G01N 33/6893 (2013.01); C07K 16/40 (2013.01); C12Q 2600/156 (2013.01)] 10 Claims
 
1. A method of treating a subject having CD55 deficiency, hyperactivation of complement, angiopathic thrombosis and protein losing enteropathy (CHAPLE), the method comprising:
selecting a subject having CD55 deficiency, hyperactivation of complement, angiopathic thrombosis and protein losing enteropathy (CHAPLE); and
administering an effect amount of a composition comprising at least one therapeutic antibody to the subject, wherein the therapeutic antibody is eculizumab, ALXN1007, neutrazumab, Pexelizumab, ofatumumab, HuMax-CD38, TNX-558, TNX-234, or TA106, thereby treating the subject having CD55 deficiency, hyperactivation of complement, angiopathic thrombosis and protein losing enteropathy (CHAPLE).